Pharm III - Substance Use Disorder

0.0(0)
Studied by 0 people
call kaiCall Kai
Locked
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/35

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 9:10 PM on 9/9/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

36 Terms

1
New cards

Med effects pts can grow tolerance to

Euphoria, sedation, respiratory depression

2
New cards

Med effects pt do NOT grow tolerance to

Anxiolytic affects, analgesia, constipation, miosis

3
New cards

Primary neurotransmitter in reward system

Dopamine

4
New cards

Area of the brain that the reward pathway connects?

Nucleus accumbens and ventral tegmental area

*stimulate VTA -> nucleus accumbens -> DA -> prefrontal cortex, enhancing reward pathway (reinforcing)

5
New cards

Withdrawal sx: nausea/vomiting, diarrhea, "goose flesh", chills, yawning, flu-like sx

Opioid withdrawal

6
New cards

Pharmacotherapy for opioid withdrawal

Methadone

Buprenorphine

Naloxone

Naltrexone

7
New cards

Methadone MOA

Mu-opioid receptor agonist

8
New cards

Buprenorphine MOA

partial mu agonist

9
New cards

Naloxone/Naltrexone MOA

Mu receptor antagonists

10
New cards

Mu receptor effects

Pain - innervations to the brain

Cravings/compulsion - reward center of brain

Physiological withdrawal - brainstem, spinal cord

11
New cards

Methadone SE

Dry mouth, constipation, nausea, loss of appetite, anxiety, insomnia, decreased sex life

12
New cards

Methadone BBW

Concurrent use w benzodiazepines -> risk of OD and death

13
New cards

Why is Naloxone added to Buprenorphine?

Minimize IV injection misuse

*should be SL for opioid tx

14
New cards

Buprenorphine SE

HA, nausea, sweating, constipation, stomach pain, sleep issues, SL irritation, cavities

15
New cards

Buprenorphine BBW

Concurrent benzodiazepines -> risk of OD and death

16
New cards

Acute pain management in patients receiving OMT

Buprenorphine - divide total daily dose into 3-4 doses

Methadone - additional methadone

17
New cards

Pharmacological effects of alcohol

Alcohol facilitates GABA action -> decreased CNS excitability. Long term it causes a decrease in GABA receptors -> tolerance

Also acts as NMDA receptor antagonist -> decreased CNS excitatory tone. Chronic use leads to increased number of NMDA receptors -> more glutamate

18
New cards

Mainstay tx for ACUTE ethanol withdrawal

Benzodiazepines

19
New cards

Treatment for alcohol DEPENDENCE (chronic tx)

Disulfiram, naltrexone, acamprosate

20
New cards

Ethanol MOA

EtOH -> acetaldehyde (step 1 metabolized by alcohol dehydrogenase, rate limiting step)

Acetaldehyde -> acetic acid (aldehyde dehydrogenase)

-> CO2 + H2O

21
New cards

Disulfiram MOA

Interferes w aldehyde dehydrogenase (step 2) -> excessive aldehyde levels -> N/V, hypotension, headaches

22
New cards

In which patients should you prescribe disulfiram?

Extremely motivated patients; disulfiram-alcohol reaction promotes abstinence

23
New cards

Naltrexone use in chronic alcoholism

Long acting opioid antagonist -> reduces craving

24
New cards

Which alcoholic pt should you avoid using naltrexone in

Any pt who is taking opioids for chronic pain

25
New cards

Acamprosate use in chronic alcoholism

Decreases glutamatergic transmission, modulates neuronal hyperexcitability during withdrawal

26
New cards

When should Acamprosate be considered when tx chronic alcoholism

Considered an alternative to naltrexone for pts who are also taking opioids or have significant hepatic impairment

27
New cards

Prescription drug monitoring program components

Patient tracking of records

Prescriber tracking of records

Surveillance/monitoring/research

28
New cards

What would you NOT find on the PDMP

Other state info (statewide program)

Methadone/buprenorphine under federal programs

29
New cards

Basic observations of CSMD report

Persistent or continued randomness of similar meds including escalating-deescalating doses, variation in doses

30
New cards

What are opioid doses compared to?

All opioids are compared to morphine on a mg/mg basis

*MEDD should be used anytime an opiate is prescribed

31
New cards

Milligram Morphine Equivalent (MME)

value assigned to opioids to represent their relative potencies

*Risk of OD doubles >50 MME/day*

MUST be under 90

32
New cards

CDC recommendations for outpatient pain prescribing

Extra precaution when increasing to >50 MME per day

- monitor and assess pain

- discuss reducing dose/tapering

- consider offering Naloxone PRN

*avoid increasing dose to >90 MME per day

33
New cards

Who should you prescribe outpatient Naloxone to?

Patients who are prescribed opioids > 50 MME

34
New cards

Naloxone use in opioid overdose

ONLY way to reverse opioid OD

Reverses effects by binding to same sites as opioids so breathing can be restored (30-90 min)

Not possible to OD on Naloxone, pt will go into temporary withdrawal

35
New cards

Where should you administer IM Naloxone

Outer thigh

36
New cards

When are prescribers required to check PDMP

Before prescribing opiates or cocaine derivatives in Schedule II drugs or benzodiazepines